• About us
• Contact

Advertisement

Product › Details

arimoclomol

	Next higher product group	pharmaceutical_oo
	Status	2007-09-24 development existent

Record changed: 2023-07-10

Advertisement

More documents for arimoclomol

• [1] Orphazyme A/S. (2/7/20). "Press Release: Orphazyme Completes Offering of 7,032,937 Shares in a Directed Issue and Private Placement and Raises approximately DKK 745,000,000 (EUR 100 Million / USD 110 Million) [Not for US, CA, JP or AU]". Copenhagen....
• [2] Orphazyme A/S. (1/30/19). "Press Release: Orphazyme Reports Positive Results from Full Data Set of Phase II/III Arimoclomol Tria in Niemann-Pick Disease Type C (NPC)". Copenhagen....
• [3] Centogene AG. (5/9/18). "Press Release: Centogene Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease". Rostock....
• [4] Orphazyme ApS. (3/8/17). "Press Release: Orphazyme Raises EUR 14 Million to Further Expand Its Clinical Development Programme"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.